Neuroplastic Consequences of Peripheral Paralysis: Evidence that Botulinum Toxin Alters Central Emotion and Motor Circuits

Abstract

Botulinum toxin type A (BoNT-A) is a neuromuscular paralytic that inhibits acetylcholine release at the peripheral junction. Although originally presumed to act only locally, a growing body of neuroimaging and neurophysiological evidence demonstrates that BoNT-A alters central processing within emotional and motor circuits. Through disruption of sensorimotor and facial feedback, the toxin induces cortical and subcortical reorganization, modulating regions such as the amygdala, prefrontal cortex, and sensorimotor homunculus. This paper reviews contemporary findings supporting the hypothesis that transient paralysis can rewire behavioral centers of the brain and periphery through neuroplastic feedback mechanisms.

Introduction

BoNT-A, widely known as Botox, operates by cleaving the SNAP-25 protein, preventing neurotransmitter release and inducing localized paralysis. However, emotion and movement are bidirectional processes: muscle activity generates proprioceptive and affective feedback that informs higher cortical regions. Disruption of this feedback loop may compel central networks to adapt, thus “rewiring” behavioral regulation systems.

Emerging studies reveal measurable neural and behavioral shifts following BoNT-A administration, challenging the historic assumption of its peripheral confinement. The evidence spans emotional modulation, sensorimotor remapping, and alterations in cortical excitability.

Emotional Circuit Modulation

Facial paralysis provides a natural experiment in embodied cognition. Stark, Stark, and Brin (2023) demonstrated reduced amygdala reactivity to emotional stimuli following glabellar BoNT-A injection, indicating that blocking frown muscles attenuates limbic arousal. Krüger et al. (2022) observed similar amygdalo-prefrontal changes in patients with borderline personality disorder, implying enhanced top-down control over negative affect.

Earlier work by Havas et al. (2010) found that participants treated with BoNT-A processed emotionally negative language more slowly, suggesting interference with affective simulation during comprehension. Collectively, these findings support the facial feedback hypothesis—that emotional experience is mediated partly by muscular feedback to the brain.

Sensorimotor Reorganization

BoNT-A also induces measurable changes in motor cortex representation. In dystonia and writer’s cramp, cortical mapping studies show contraction of hyperactive motor fields and normalization of inter-hemispheric balance after injection (Byrnes et al., 1998; Boroojerdi et al., 2003). Functional MRI in stroke survivors revealed that BoNT-A treatment reduces pathological overactivation in motor and premotor areas while improving motor control (Bergfeldt et al., 2015; Vinehout et al., 2021).

These results suggest that peripheral chemodenervation triggers central recalibration, echoing Hebbian principles: when certain sensory inputs are silenced, the cortex reallocates processing resources to restore functional equilibrium.

Central Plasticity and Mechanisms

Neurophysiological investigations demonstrate BoNT-A’s influence on synaptic plasticity and neurotransmission beyond the injection site. Kojović et al. (2011) reported reduced associative plasticity in dystonia patients post-injection, consistent with homeostatic regulation within the basal ganglia–thalamocortical loop. Animal studies reviewed by Luvisetto (2021) describe altered hippocampal protein expression and memory performance following peripheral BoNT-A administration, suggesting broader neuromodulatory capacity.

The prevailing hypothesis holds that altered afferent feedback from muscle spindles reorganizes cortical and subcortical activity, indirectly “rewiring” the motor and emotional networks through adaptive plasticity.

Discussion and Implications

The intersection of paralysis and plasticity highlights a paradox: immobilizing the periphery can liberate the cortex from maladaptive patterns. These findings offer therapeutic implications for mood disorders, dystonias, and post-stroke rehabilitation. However, they also raise ethical questions regarding affective blunting and the long-term neurobehavioral impact of repeated cosmetic use.

The embodied brain does not end at the skull, it is distributed across nerve, fascia, and motion. To silence one part is to compel the whole to adapt.

References

Bergfeldt, U., Jonsson, T., Bergfeldt, L., Julin, P., & Borg, J. (2015). Cortical activation changes and improved motor function in stroke patients after focal spasticity therapy—an interventional study applying repeated fMRI. BMC Neurology, 15, 52. https://doi.org/10.1186/s12883-015-0303-x

Boroojerdi, B., Kopper, F., Prager, A., Muellbacher, W., & Deuschl, G. (2003). Effects of botulinum toxin on motor system excitability in patients with writer’s cramp. Neurology, 61(11), 1546–1550. https://doi.org/10.1212/01.WNL.0000095965.31345.AC

Byrnes, M. L., Thickbroom, G. W., Wilson, S. A., Sacco, P., Shipman, J. M., Stell, R., & Mastaglia, F. L. (1998). The corticomotor representation of upper limb muscles in writer’s cramp and changes following botulinum toxin injection. Brain, 121(5), 977–988. https://doi.org/10.1093/brain/121.5.977

Havas, D. A., Glenberg, A. M., Gutowski, K. A., Lucarelli, M. J., & Davidson, R. J. (2010). Cosmetic use of botulinum toxin-A affects processing of emotional language. Psychological Science, 21(7), 895–900. https://doi.org/10.1177/0956797610374742

Kojović, M., Caronni, A., Bologna, M., Rothwell, J. C., Bhatia, K. P., & Edwards, M. J. (2011). Botulinum toxin injections reduce associative plasticity in patients with primary dystonia. Movement Disorders, 26(7), 1282–1289. https://doi.org/10.1002/mds.23644

Krüger, T. H. C., Grimm, S., Rist, F., et al. (2022). Neuronal effects of glabellar botulinum toxin injections using a valenced inhibition task in borderline personality disorder. Scientific Reports, 12, 13727. https://doi.org/10.1038/s41598-022-17509-0

Luvisetto, S. (2021). Botulinum neurotoxins in central nervous system: An overview from animal models to human therapy. Toxins, 13(11), 751. https://doi.org/10.3390/toxins13110751

Stark, S. M., Stark, C. E. L., & Brin, M. F. (2023). Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning. Scientific Reports, 13, 1750. https://doi.org/10.1038/s41598-023-29280-x

Vinehout, K., McCully, K., Kluding, P., et al. (2021). Changes in cortical activity in stroke survivors following upper-limb botulinum toxin therapy: An fMRI study. Frontiers in Rehabilitation Sciences, 2, 735819. https://doi.org/10.3389/fresc.2021.735819